Did You Know?

Editor’s Picks

Latest News

Ambros Therapeutics Announces First Patient Dosed in Pivotal CRPS-RISE Phase 3 Clinical Trial of Neridronate in Patients with Complex Regional Pain Syndrome Type 1

CRPS-RISE designed to support FDA regulatory submission for potential approval of neridronate in patients with CRPS-1FDA has previously granted neridronate...

AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer

Medera Expands Scientific Advisory Board with Leading Heart Failure and Cardiopulmonary Physiology Experts to Advance HFpEF Gene Therapy Program

Appointments further strengthen clinical leadership as Medera advances its First-In-Human HFpEF gene therapy program toward key upcoming milestonesBOSTON, June 08,...

Red Light Holland’s Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Study at GHU Paris Psychiatrie & Neurosciences in France

error: Content is protected !!